Drugs

FDA: PDUFA 7 CMC Commitments Complete

David McFarland

— 2 min read
Share

FDA has published a strategy document on facilitating Chemistry, Manufacturing, and Controls (CMC) readiness for products with accelerated clinical development. The document says its publication completes the four CMC items the agency agreed to do under PDUFA 7.

The strategy document says FDA:

  • published a CDER Manual of Policies and Procedures (MAPP) on quality assessment for products in expedited programs;
  • obtained stakeholder feedback from a CMC Development and Readiness Pilot workshop;
  • shared what was learned from the readiness pilot; and
  • published the required strategy document.

FDA says it will stop accepting new applications to participate in the development and readiness pilot at the end of 4/2027. It says that after a review of the PDUFA 7 commitments, the agency has determined that it is not necessary at this time to develop or revise relevant MAPPs, Standard Operating Policies and Procedures, or other documents. “However,” it adds, “lessons learned from the pilot will continue to be incorporated into ongoing initiatives, programs, and activities” in terms of (1) ways of working and communicating and (2) regulatory flexibility.

The pilot was created to help developers of drugs and biologics for serious conditions overcome manufacturing and quality-related hurdles that can delay products with accelerated clinical development timelines. Although FDA will stop accepting new participants into the pilot in 2027, it says the lessons learned will continue to shape how the agency works with sponsors pursuing expedited development programs.

Specifically, FDA found that early, frequent communication between regulators and sponsors helped companies better address CMC challenges, strengthen marketing applications, and reduce the risk of regulatory delays. Participants valued rapid, iterative feedback through meetings, phone calls, and email exchanges, which often provided greater clarity than traditional meeting schedules. The agency also highlighted existing regulatory flexibilities, including alternative approaches to process validation, stability testing, and the use of clinical-scale manufacturing, that can help speed product development without compromising product quality.

Participation in the pilot, however, fell well below capacity. Over its first three years, FDA accepted only 10 products despite having room for up to 27. Industry groups cited several barriers, including uncertainty about eligibility, the effort required to prepare detailed CMC development plans, concerns over confidentiality, and limited additional value for products already receiving expedited designations such as Breakthrough Therapy or RMAT. In response, the agency streamlined the application process by reducing review times, relaxing eligibility requirements, and simplifying documentation, although overall participation remained modest.

Rather than creating new policies, the FDA plans to incorporate the pilot's successful practices into existing expedited review programs. The agency will continue encouraging sponsors to develop CMC strategies earlier, hold CMC-focused meetings throughout development, and use mechanisms that provide faster regulatory feedback. Existing guidance on quality assessment for expedited products and recent CMC flexibility guidance for cell and gene therapies will remain in effect, reflecting FDA's conclusion that the pilot's lessons can be integrated into current regulatory frameworks without additional formal policy changes.

Read more